Erratum: Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea (JAMA Neurology (2017) 74:8 (977-982) DOI: 10.1001/jamaneurol.2017.1352);Safety of converting from tetrabenazine to deutetrabenazine for the treatment of Chorea

JAMA Neurology

Volumn 74, Issue 8, 2017, Pages 977-982

  Frank, Samuel ^a   Stamler, David ^b   Kayson, Elise ^c   Claassen, Daniel O ^d   Colcher, Amy ^e   Davis, Charles ^f   Duker, Andrew ^g   Eberly, Shirley ^c   Elmer, Lawrence ^h   Furr Stimming, Erin ⁱ   Gudesblatt, Mark ^j   Hunter, Christine ^k   Jankovic, Joseph ^k   Kostyk, Sandra K ^l   Kumar, Rajeev ^m   Loy, Clement ⁿ   Mallonee, William ^e   Oakes, David ^o   Scott, Burton L ^p   Sung, Victor ^q   Goldstein, Jody ^c   Vaughan, Christina ^r   Testa, Claudia M ^s   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b Teva Pharmaceutical Industries   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^f CSD Biostatistics   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h Center for Neurologic Health   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j South Shore Neurologic Associates   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m Rocky Mountain Movement Disorders Center   (United States)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o UNIVERSITY OF ROCHESTER   (United States)

^p DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^r MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^s VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEUTETRABENAZINE; DRUG METABOLITE; TETRABENAZINE; ADRENERGIC RECEPTOR AFFECTING AGENT;

ADULT; ANXIETY; ARTICLE; CHOREA; CLINICAL ARTICLE; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROCARDIOGRAM; FALLING; FEMALE; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; LABORATORY TEST; MALE; MIDDLE AGED; MOTOR PERFORMANCE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; UNIFIED HUNTINGTON DISEASE RATING SCALE; VITAL SIGN; XEROSTOMIA; ANALOGS AND DERIVATIVES; AUSTRALIA; CLINICAL TRIAL; FOLLOW UP; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC UPTAKE INHIBITORS; AUSTRALIA; CHOREA; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TETRABENAZINE; TREATMENT OUTCOME; UNITED STATES;

EID: 85027458623     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.3563     Document Type: Erratum

References (15)

1. Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacological treatment of chorea in Huntington's disease. PLoS Curr. 2011; 3:RRN1260.
2. Jankovic J, Roos RA. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord. 2014; 29(11):1414-1418.
3. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007; 22(2):193-197.
4. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016; 17(18):2461-2470.
5. Austedo™ [package insert]. North Wales, PA: Teva Pharmaceuticals Inc; 2017.
6. Frank S, Testa CM, Stamler D, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington Disease: a randomized clinical trial. JAMA. 2016; 316(1):40-50.
7. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord. 1995; 10(2):211-214.
8. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996; 11(2):136-142.
9. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67 (6):361-370.
10. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-1277.
11. Barnes TR A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154:672-676.
12. Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord. 2007; 22(13): 1917-1921.
13. Fahn S, Elton RL; Members of the UDC. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163.
14. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-699.
15. Johns MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-545.